| Methods |
Single centre, double‐blind, placebo‐controlled
Randomisation by next random number on list
60 patients randomised but 8 excluded due to incorrect diagnosis
Data from paper, PP analysis |
| Participants |
German
52 patients: T: 24, C: 28
Mean age T: 64, C: 65 (efficacy)
Males 38
Inclusion: ischaemic stroke of mild to moderate severity (Mathew scale sum between 50 and 75), > 39 years and < 85 years
Diagnosis: clinical and 100% CT scan
Enrolment within 48 hours |
| Interventions |
T: nimodipine 30 mg po qid
C: matching po placebo
Rx: for 14 days
Medical therapy allowed such as drugs against infection, hypertension, mild hypnotics, analgesics, volume substitution (including Dextran 40), low‐dose heparin (2 x 500 U/day) |
| Outcomes |
Impairment: Mathews score on day 1, 3, 5, 7, and 14, week 4 and month 4
BP and heart rate were checked twice daily and on week 4 and month 4
Number of hypotensives noted
Method used for taking BP not given |
| Notes |
Ex: TIA, progressing stroke, coma, brain stem, ICH, SAH, recent MI, CCF, systemic infection, renal/hepatic failure, SBP < 100, DBP > 105, bradycardia (heart rate < 50 beats/minute), AV conduction disturbances, concomitant use of CCBs, piracetam, pentoxifylline, naftidrofuryl hydrogenoxalate, dihydroergotoxine, alpha methyl dopa
Follow up 4 weeks and 4 months |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Low risk |
Randomisation by next random number on the list |
| Allocation concealment? |
Low risk |
Probably done |
| Blinding? |
Low risk |
Probably done |
| Completeness of follow‐up |
Unclear risk |
Unclear from the publication |
